ESPL1

Across TCGA pan-cancer cohorts, ESPL1 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated ESPL1 data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ESPL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ESPL1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LIHC, LUAD, and ACC are the cancer types where ESPL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.173	0.710	<.001	36	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	19	view →
ACC	DFS	Median	All	0.193	0.659	.004	15	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
CESC	OS	Median	II,III,IV	0.252	0.764	.006	12	view →
LUSC	DFS	Median	II,III,IV	0.129	0.684	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	OS	Median	All	0.349	0.683	.022	6	view →
SKCM	OS	Median	II,III,IV	1.000	0.832	.012	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
GBM	OS	Median	All	0.199	0.422	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

ESPL1–LIHC (OS)

Open the LIHC breakdown →